Skip to main content
Log in

21. Cardiac Ischemic Outcomes and Hospitalizations in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome Treated with Alogliptin or Placebo: New Insights from the EXAMINE Trial (13-OR)

  • Congresverslag
  • Published:
Nederlands Tijdschrift voor Diabetologie Aims and scope

Samenvatting

Background: Concerns have been raised regarding adverse cardiovascular outcomes with new therapies for type 2 diabetes (T2DM). The EXAMINE trial studied the effect of the DPP-4 inhibitor alogliptin on major CV events in patients with T2DM and recent acute coronary syndromes. Herein we present data on all cardiac ischemic events and cardiovascular hospitalizations (CVHs) in EXAMINE. Methods: Data from all 5380 patients randomized in EXAMINE were used. The incident rates of MI and unstable angina, coronary revascularization, CVH, and composites of these ischemic endpoints were calculated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

Authors

Additional information

Boston, MA, Deerfield, IL, Cleveland, OH, Vandoeuvre-lès-Nancy, France, Farmington, CT

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shimada, Y., Cannon, C., Wilson, C. et al. 21. Cardiac Ischemic Outcomes and Hospitalizations in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome Treated with Alogliptin or Placebo: New Insights from the EXAMINE Trial (13-OR). Ned Tijdschr Diabetol 13, 76–77 (2015). https://doi.org/10.1007/s12467-015-0042-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12467-015-0042-9

Navigation